# Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01169818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01169818](<https://clinicaltrials.gov/study/NCT01169818>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01169818

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 555 participants.

## Technical summary

Registry record NCT01169818. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 555 participants (enrolled count; ClinicalTrials.gov record NCT01169818, source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01169818, source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01169818, source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)
- Completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01169818, source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)
- Countries: China; India; Japan; Pakistan; Philippines; Russia (ClinicalTrials.gov record NCT01169818, source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01169818-2013-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
- Acronym: ATLAS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study (`cardio:pubmed-25297660`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6d3f21de17747a628fa159db7053b616fb63c21f0377e169d6c50af31f1ce838
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
